The Huntington's Disease Treatment Market is evolving as the healthcare industry places greater emphasis on genetic medicine and targeted therapies for complex neurological conditions. The market is forecast to grow from USD 2.1 billion in 2025 to USD 3.5 billion by 2035, representing a CAGR of 5.4%.

Research and development is one of the most important forces influencing the market. Pharmaceutical and biotechnology companies are investigating therapies that target the genetic mechanisms associated with Huntington's disease, while academic research is improving understanding of HTT-related pathways. These efforts could expand treatment options beyond conventional symptom management.

Among treatment categories, antipsychotics hold the largest share and are projected to increase from USD 900 million in 2024 to USD 1.5 billion in 2035. Their role in managing psychiatric and behavioral symptoms keeps them central to current treatment strategies, while neuroprotective agents and other emerging approaches offer opportunities for future therapeutic innovation.

North America continues to dominate due to its advanced healthcare infrastructure and substantial research activity. Europe benefits from collaborative research and supportive regulatory frameworks, while Asia Pacific is expected to expand as governments increase healthcare investment and neurological research capabilities. South America and the Middle East and Africa are also expected to develop gradually as healthcare infrastructure improves.

Digital healthcare could become another important growth area. Telemedicine, remote patient monitoring, and AI-based analytics can help specialists follow treatment responses and support patients who have limited access to neurological care. Combined with advances in precision medicine and gene therapy, these technologies could improve treatment personalization and create new commercial opportunities.